These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 16333527)
1. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527 [TBL] [Abstract][Full Text] [Related]
2. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Hiscox S; Jordan NJ; Smith C; James M; Morgan L; Taylor KM; Green TP; Nicholson RI Breast Cancer Res Treat; 2009 May; 115(1):57-67. PubMed ID: 18493848 [TBL] [Abstract][Full Text] [Related]
3. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation. Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830 [TBL] [Abstract][Full Text] [Related]
4. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Hiscox S; Barnfather P; Hayes E; Bramble P; Christensen J; Nicholson RI; Barrett-Lee P Breast Cancer Res Treat; 2011 Feb; 125(3):659-69. PubMed ID: 20354780 [TBL] [Abstract][Full Text] [Related]
7. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500 [TBL] [Abstract][Full Text] [Related]
8. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201 [TBL] [Abstract][Full Text] [Related]
9. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397 [TBL] [Abstract][Full Text] [Related]
10. Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells. Andersen P; Villingshøj M; Poulsen HS; Stockhausen MT Cancer Invest; 2009 Feb; 27(2):178-83. PubMed ID: 19235590 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Hiscox S; Morgan L; Barrow D; Dutkowskil C; Wakeling A; Nicholson RI Clin Exp Metastasis; 2004; 21(3):201-12. PubMed ID: 15387370 [TBL] [Abstract][Full Text] [Related]
12. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437 [TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Fan P; Wang J; Santen RJ; Yue W Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173 [TBL] [Abstract][Full Text] [Related]
14. Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways. Chen PH; Peng CY; Pai HC; Teng CM; Chen CC; Yang CR J Nutr Biochem; 2011 Aug; 22(8):732-40. PubMed ID: 21062671 [TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379 [TBL] [Abstract][Full Text] [Related]
16. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Hiscox S; Jiang WG; Obermeier K; Taylor K; Morgan L; Burmi R; Barrow D; Nicholson RI Int J Cancer; 2006 Jan; 118(2):290-301. PubMed ID: 16080193 [TBL] [Abstract][Full Text] [Related]
17. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Hiscox S; Jordan NJ; Morgan L; Green TP; Nicholson RI Clin Exp Metastasis; 2007; 24(3):157-67. PubMed ID: 17394086 [TBL] [Abstract][Full Text] [Related]
18. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Hiscox S; Morgan L; Green T; Nicholson RI Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S53-9. PubMed ID: 17259559 [TBL] [Abstract][Full Text] [Related]
19. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
20. A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Brunton VG; Ozanne BW; Paraskeva C; Frame MC Oncogene; 1997 Jan; 14(3):283-93. PubMed ID: 9018114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]